Health Care & Life Sciences » Pharmaceuticals | Paratek Pharmaceuticals Inc.

Paratek Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Paratek Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
HBM BioVentures Ltd.
895,000
2.82%
70,000
0.62%
12/31/2017
Vanguard Total Stock Market Index Fund
805,979
2.54%
44,800
0%
07/31/2018
iShares Russell 2000 ETF
659,263
2.08%
-351
0.01%
09/06/2018
Government Pension Fund - Global (The)
526,977
1.66%
430,477
0%
12/31/2017
Vanguard Extended Market Index Fund
379,624
1.2%
0
0.01%
07/31/2018
iShares Nasdaq Biotechnology ETF
367,471
1.15%
-4,809
0.04%
09/06/2018
Carnegie Fund - Medical
341,200
1.08%
0
0.61%
08/31/2018
General American Investors Fund
308,864
0.97%
-38,349
0.21%
12/31/2017
iShares Russell 2000 Growth ETF
303,517
0.96%
0
0.03%
09/06/2018
JPMorgan US Small Companies Fund
278,800
0.88%
5,500
0.15%
07/31/2018

About Paratek Pharmaceuticals

View Profile
Address
75 Park Plaza
Boston Massachusetts 02116
United States
Employees -
Website http://www.paratekpharma.com
Updated 07/08/2019
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include Omadacycline and Sarecycline, which are used for the treatment of serious community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, and urinary tract infections. The company was founded in February 2001 and is headquartered in Boston, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.